HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Indaptus Therapeutics (NASDAQ:INDP) and maintained a $12 price target.
August 11, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $12.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Indaptus Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100